Raymond James upgraded shares of bluebird bio (NASDAQ:BLUE – Get Rating) from a market perform rating to an outperform rating in a report published on Tuesday morning, Marketbeat reports. They currently have $8.00 target price on the biotechnology company’s stock.
Several other research firms also recently weighed in on BLUE. Cowen downgraded bluebird bio from an outperform rating to a market perform rating in a research note on Wednesday, April 6th. SVB Leerink dropped their price target on bluebird bio from $10.00 to $8.00 and set a market perform rating on the stock in a research note on Wednesday, April 6th. Morgan Stanley dropped their price target on bluebird bio to $3.00 and set an underweight rating on the stock in a research note on Tuesday, May 17th. Wedbush decreased their price objective on bluebird bio from $10.00 to $8.00 and set a neutral rating for the company in a report on Tuesday, May 10th. Finally, Barclays decreased their price objective on bluebird bio from $4.00 to $3.00 in a report on Tuesday, May 10th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, bluebird bio currently has a consensus rating of Hold and an average target price of $11.71.
bluebird bio Trading Up 7.7 %
BLUE opened at $4.04 on Tuesday. The firm has a market cap of $288.66 million, a price-to-earnings ratio of -0.38 and a beta of 1.29. bluebird bio has a 12 month low of $2.87 and a 12 month high of $26.07. The stock has a fifty day moving average price of $4.12 and a 200-day moving average price of $4.84.
Hedge Funds Weigh In On bluebird bio
Hedge funds have recently made changes to their positions in the company. Amalgamated Bank purchased a new stake in shares of bluebird bio in the first quarter valued at approximately $39,000. US Bancorp DE grew its position in shares of bluebird bio by 82.9% in the first quarter. US Bancorp DE now owns 8,486 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 3,847 shares in the last quarter. Raymond James & Associates purchased a new stake in shares of bluebird bio in the first quarter valued at approximately $50,000. Penserra Capital Management LLC purchased a new stake in shares of bluebird bio in the first quarter valued at approximately $53,000. Finally, Bank of Montreal Can purchased a new stake in shares of bluebird bio in the first quarter valued at approximately $58,000. Institutional investors and hedge funds own 96.38% of the company’s stock.
bluebird bio Company Profile
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.